SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-220546
Filing Date
2022-08-15
Accepted
2022-08-15 07:11:03
Documents
15
Period of Report
2022-08-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d345691d8k.htm   iXBRL 8-K 39472
2 EX-10.1 d345691dex101.htm EX-10.1 422395
3 EX-99.1 d345691dex991.htm EX-99.1 13622
7 GRAPHIC g345691g0812210356819.jpg GRAPHIC 1830
  Complete submission text file 0001193125-22-220546.txt   728391

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA atai-20220809.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20220809_lab.xml EX-101.LAB 18670
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20220809_pre.xml EX-101.PRE 11670
9 EXTRACTED XBRL INSTANCE DOCUMENT d345691d8k_htm.xml XML 3531
Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 (617) 699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 221162292
SIC: 2834 Pharmaceutical Preparations